INTRODUCTION
============

*TBX3* is a member of the T-box gene family that encodes DNA-binding transcription factors with well-defined roles in embryonic development. *Tbx3* plays critical roles in a variety of developmental processes, including maintenance of stem cells, cell-fate determination, and organogenesis. It has been shown to promote self-renewal of embryonic stem cells through up-regulation of the pluripotency factor Nanog ([@B27]; [@B53]), and when coexpressed with Oct4, Sox2, and Klf4, Tbx3 improves the ability of induced pluripotent stem cells to colonize germ tissues and produce viable offspring ([@B24]). *Tbx3* has also been shown to control the proliferation and cell-fate determination of multipotent hepatic progenitor cells in the developing liver ([@B68]). During heart development, *Tbx3* contributes to the specification of the atrioventricular conduction system, which coordinates contraction of the heart ([@B3]), as well as correct development of the outflow tract ([@B45]). In humans, *TBX3* is expressed in the fetal lung, kidney, heart, liver, and spleen ([@B5]), and *Tbx3* homozygous mutant mice die in utero with abnormalities in the limbs, genitalia, and mammary glands ([@B15]; [@B28]). In the mouse, the hindlimb is truncated, whereas the forelimb is less severely affected with abnormal or missing posterior elements ([@B15]).

Of importance, dosage sensitivity to *TBX3* has been reported, which is underscored by observations that mutations that lead to haploinsufficiency of the human *TBX3* gene result in ulnar-mammary syndrome. This syndrome is characterized by malformations of the apocrine glands, genitalia, hair, teeth, and limbs, including severe reduction of the posterior elements of the forelimb, with rare involvement of the hindlimb ([@B6]), in contrast to the mouse, in which the hindlimb is always more severely affected ([@B15]). In addition, several lines of evidence suggest that overexpression of *TBX3* may be a critical step in oncogenesis. *TBX3* levels are up-regulated in a number of breast cancer cell lines, some small cell lung cancers, rat bladder carcinomas, and liver tumors ([@B26]; [@B33]; [@B59]) and is detected in the plasma of \>80% of ovarian cancer and breast cancer patients ([@B33]). Recent data by [@B56] demonstrate that overexpression of *TBX3* in melanoma and breast cancer cells is responsible for tumor formation, metastasis, and invasion, potentially through its ability to suppress E-cadherin expression. This is consistent with a study by [@B64], which showed that TBX3 directly represses E-cadherin expression and that later stages of melanoma progression correlate with elevated levels of *TBX3* and decreased levels of E-cadherin. An understanding of how *TBX3* expression is regulated thus has implications for its role in embryonic development, as well as for shedding light on its contribution to oncogenesis. However, only a few signaling pathways governing *Tbx3* expression have been described.

A study by [@B59] demonstrated that *Tbx3* is downstream of the Wnt/β-catenin signaling pathway in liver cancers and in particular that an active, mutant form of β-catenin transcriptionally up-regulated *Tbx3*. More recently, protein kinase C signaling was shown to activate *TBX3* expression via the AP-1 transcription factors c-Jun and JunB, and this was shown to be important in promoting breast cancer cell migration ([@B47]). Although the phosphotidylinositol-3-OH kinase-Akt, mitogen-activated protein kinase, and bone morphogenetic protein (BMP) pathways have also been implicated in the regulation of *Tbx3* ([@B8]; [@B53]), the details of the mechanisms involved have yet to be elucidated. The developmentally important retinoic acid (RA) signaling pathway has also been implicated in the regulation of certain T-box family members. For example, chick embryos exposed to ectopic RA showed an overall repression of *Tbx1* expression ([@B63]) but an expansion of *Tbx5* expression in the atrium of the heart ([@B29]). Furthermore, an investigation by [@B69] revealed that in chick limbs implanted with RA-soaked beads, there was an expansion in expression of both *Tbx3* and its closely related family member *Tbx2*. Consistent with these data, [@B72] demonstrated a loss of posterior *Tbx3* expression in the leg bud of retinoid-deficient quail. Although these studies are suggestive that RA may be able to regulate *Tbx3* gene expression, the precise mechanisms of this regulation are not known, and whether these effects are reproducible in a mammalian model system has not been shown.

During development, RA is produced by the conversion of retinaldehyde sourced from maternal retinoids by retinaldehyde dehydrogenases (Raldh1, 2, and 3). RA activates the nuclear RA receptors (RARs) and retinoid X receptors (RXRs; reviewed in [@B7]). These receptors function as a RA-binding heterodimer that regulates target gene transcription via a retinoic acid response element (RARE; [@B40]). The importance of RA signaling in embryogenesis is highlighted by reports describing numerous developmental defects in mouse embryos in which Raldh2 is knocked out or when different isoforms of the RARs are mutated together. These defects include compromised formation of the brain, pancreas, heart, lungs, limbs, and skeleton ([@B32]; [@B42]; [@B52], [@B49]; [@B41]; [@B61]). Given that RA and *Tbx3* have been implicated in the development of several common organs, we wanted to explore the possibility that *Tbx3* may be downstream of the RA signaling pathway. Indeed, here we show, using in vitro and in vivo assays, that the RA--receptor complex directly binds the *TBX3* promoter to activate *TBX3* expression, and we provide evidence that this regulation is functionally relevant in mouse embryonic limb development.

RESULTS
=======

Retinoic acid transcriptionally activates TBX3 gene expression
--------------------------------------------------------------

The development of several organs, including the heart, kidney, and limbs require both RA and Tbx3 ([@B31]; [@B5]), raising the interesting possibility that they act in sequence or in parallel during organogenesis. To begin to address this question, we first tested whether *Tbx3* expression can be regulated by RA in cultured cells, using the ME1402 human melanoma line, which expresses endogenous TBX3 ([@B56]). ME1402 cells were treated with 10 μM all-*trans* retinoic acid or dimethyl sulfoxide (DMSO) vehicle over a time course spanning 2--24 h. Western blot analyses show that TBX3 levels increase with RA at all time points tested ([Figure 1A](#F1){ref-type="fig"}), indicating that RA is able to rapidly up-regulate expression of TBX3 protein. Quantitative real-time PCR (qRT-PCR) experiments carried out on cells treated with RA for 4 h show a corresponding increase in *TBX3* mRNA levels ([Figure 1B](#F1){ref-type="fig"}), suggesting that RA may regulate *TBX3* transcriptionally. This was confirmed in experiments in which the pretreatment of ME1402 cells with actinomycin D (a transcriptional inhibitor) abolished the 4-h RA-mediated increase of *TBX3* protein ([Figure 1C](#F1){ref-type="fig"}) and mRNA ([Figure 1D](#F1){ref-type="fig"}) levels. Moreover, pretreatment of ME1402 cells with cycloheximide (an inhibitor of de novo protein synthesis) did not abolish the activation of TBX3 mRNA levels by RA ([Figure 1E](#F1){ref-type="fig"}), indicating that the RA signaling pathway directly regulates TBX3 transcription.

![Retinoic acid activates human *TBX3* mRNA and protein levels. ME1402 cells were treated with either vehicle (DMSO) or 10 μM RA. (A) Protein prepared from the indicated times was analyzed by Western blotting with an antibody to TBX3, and p38 was used as a loading control. The bar graph compares the relative intensity of each TBX3 band normalized to the p38 loading control. (B) The cells were treated with RA for 4 h, and total RNA was extracted. Quantitative real-time PCR was performed on reverse-transcribed RNA using primers specific to *TBX3*, and mRNA levels were normalized to GUSB. (C, D) Cells were pretreated with vehicle (control) or 5 μg/ml actinomycin D (AD) for 1 h and then treated with RA for 4 h, and protein and RNA were harvested for use in (C) Western blot analysis and (D) real-time PCR as described in A and B, respectively. The bar graph in C compares the relative intensity of each TBX3 band normalized to the p38 loading control. (E) Cells were pretreated with vehicle (control) or 30 μg/ml cycloheximide (CHX) for 1 h and then treated with RA for 4 h and RNA harvested for use in real-time PCR as described in B. Bars, SD. \*p \< 0.05, \*\*p \< 0.001.](2362fig1){#F1}

RA receptors are likely to be direct transcriptional regulators of *TBX3*
-------------------------------------------------------------------------

The results shown in [Figure 1](#F1){ref-type="fig"} suggested that the RA-mediated increase in *TBX3* mRNA and protein levels is a direct transcriptional effect. Analysis of the 5′ regulatory region of the *TBX3* gene revealed several putative RAREs ranging from −59 to −748 base pairs upstream of the transcription start site ([Figure 2A](#F2){ref-type="fig"}). To investigate whether RA could activate expression via these putative RAREs, we performed transient cotransfection experiments using 501mel cells cotransfected with RAR and RXR expression vectors along with a luciferase vector containing 831 base pairs of *TBX3* 5′-flanking sequence. In the presence of RA, we observed a significant increase in luciferase reporter activity ([Figure 2B](#F2){ref-type="fig"}), indicating that this region of the *TBX3* promoter is likely to harbor a RARE(s). To further localize the putative RARE(s), we tested whether progressively deleting parts of the *TBX3* promoter would abolish RA-dependent transactivation. We found that constructs containing 141 base pairs or more of *TBX3* 5′-flanking sequence could induce RA-dependent reporter expression, indicating that the RARE is likely to reside in the region 141 base pairs upstream from the transcriptional start site ([Figure 2B](#F2){ref-type="fig"}).

![Retinoic acid activation of the *TBX3* promoter is mediated by a degenerate RARE half site at −75 base pairs. (A) Schematic representation of human *TBX3* deletion constructs. The arrow indicates the transcription start site at +1, and the asterisk indicates the putative RAREs. (B) 501mel cells cotransfected with *TBX3*-Luc deletion constructs and vectors expressing human RARα and RXRα were treated with vehicle (DMSO) or RA (white and black bars, respectively). Luciferase activity was measured 48 h posttransfection. (C) Alignment of the −150--base pair region of human, mouse, and zebrafish Tbx3 promoters. Sequence shown extends from −103 to −53 base pairs in the human TBX3 promoter, with a border outlining each RARE half-site. (D) WT- or MT-*TBX3* promoter luciferase constructs shown were transfected into 501mel cells and treated as in B and luciferase activity analyzed. For B and D the fold activation values were calculated by setting promoter activity of untreated cells to 1. Mean values (±) were calculated from three independent experiments. (E) Biotinylated DNA probes of the *TBX3* promoter (−137/+36 base pairs) containing the WT or MT RARE were generated by PCR, immobilized on streptavidin beads, and incubated with nuclear extracts from ME1402 cells treated with 10 μM RA for 4 h. The DNA-bound protein complexes were isolated and analyzed by Western blotting using antibodies to RARα, RARβ, RARγ, and RXRα. (F) ME1402 cells were treated with 10 μM RA for 4 h and chromatin immunoprecipitation assays performed with antibodies against RARα, RARβ, RARγ, and RXRα (RRs) or IgG (negative control). Immunoprecipitated DNA was assayed by PCR with primers against the *TBX3* promoter or GAPDH (negative control). Bars, SD. \*p \< 0.05, \*\*p \< 0.001.](2362fig2){#F2}

Scanning and sequence alignment of this region revealed a degenerate RARE at −87 base pairs that was highly conserved between human, mouse, and zebrafish *Tbx3* promoters ([Figure 2C](#F2){ref-type="fig"}). Furthermore, the half-sites at −87 and −75 base pairs comprising this putative degenerate RARE contain conserved, repeated TCA motifs, which are often observed in RAREs ([@B12]; [@B17]; [@B16]), and a nonconsensus spacer region of 6 base pairs separating the half-sites, which is in the range of previously described spacers of 1, 2, 3, 8, and 11 base pairs ([@B35]; [@B38]; [@B17]; [@B12]; [@B16]). Of interest, the −75--base pair half-site may also form a putative RARE with a half-site at −59 base pairs, although this half-site is not as evolutionarily conserved as the one at −87. To test whether the RARE half-site at −75 base pairs was required for RA-dependent expression of the *TBX3*-luciferase reporter, we examined the effect of mutating this sequence on promoter activity. We transfected 501mel cells with constructs containing either the wild-type (WT) or mutant (MT) luciferase vectors along with RAR and RXR expression vectors and measured luciferase reporter activity. As expected, the construct containing the WT RARE half-site at −75 base pairs efficiently activated luciferase activity ([Figure 2D](#F2){ref-type="fig"}). In contrast, luciferase activity was much lower in cultures transfected with the mutant *TBX3* promoter. It is worth noting that when the RARE half-site at −75 base pairs was mutated, reduction but not loss of basal TBX3 promoter activity was observed, suggesting that this site may also play a role in basal TBX3 promoter activity (unpublished data).

Using a DNA affinity immunoblot (DAI) in vitro assay, we next sought to determine whether RA receptors were able to bind the identified RAREs in the *TBX3* promoter. Nuclear extracts from RA-treated ME1402 cells were incubated with biotinylated DNA probes containing either the wild-type or mutant *TBX3* RARE. Protein-bound biotinylated DNA was isolated and analyzed by Western blotting using antibodies specific to RARα, RARβ, RARγ, and RXRα to determine which RARs and RXRs could bind to the sequence. The results show that, with the exception of RARβ, all the RA receptors tested bound the probe carrying the WT −75--base pair RARE half-site in the *TBX3* promoter and displayed a decreased affinity for this site when it was mutated ([Figure 2E](#F2){ref-type="fig"}). RARβ, however, bound the probe carrying the mutated RARE at −75 base pairs even more strongly than the WT probe.

To establish whether RA receptors are able to bind to the *TBX3* promoter in vivo, we performed chromatin immunoprecipitation assays. RA-treated ME1402 cells were fixed with formaldehyde, and the cross-linked chromatin was extracted and sheared. RA-bound chromatin was immunoprecipitated with appropriate antibodies, and after reversing the cross-link, a set of primers spanning the putative RARE half-sites at −87, −75, and −59 base pairs in the *TBX3* promoter was used to amplify the immunoprecipitated DNA. The result obtained ([Figure 2F](#F2){ref-type="fig"}) indicated that a specific PCR product was detected when using a mixture of retinoic acid receptor antibodies but not with the nonspecific immunoglobulin G (IgG) control. PCR conducted with primers against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a negative control. Taken together, the data presented here suggest that the RA transcriptional complex both binds to and directly activates *TBX3* gene expression.

RA-mediated increase in TBX3 levels correlates with a decrease in cell number
-----------------------------------------------------------------------------

RA has been shown to be an effective chemopreventative agent in clinical trials on breast cancer due to its antiproliferative effects on cell cycle arrest, differentiation, and apoptosis, and we recently showed that *TBX3* may be a novel target for anticancer drugs ([@B56]). Of importance, although knocking down *TBX3* in breast cancer and melanoma cells inhibited tumor formation and invasion, it led to an increase in cell proliferation. We were therefore interested to determine the effects of RA on the proliferation of ME1402 melanoma cells over a period of 7 d. As an indirect measure of proliferation, growth curve analyses of cells grown in the presence of RA showed a significant decrease in cell numbers compared with untreated cells ([Figure 3A](#F3){ref-type="fig"}, left), which correlated with an increase in TBX3 protein levels ([Figure 3A](#F3){ref-type="fig"}, right). These results suggested that the RA-mediated decrease in ME1402 cell number might depend on activation of *TBX3* expression. To explore this possibility, we generated a stable knockdown *TBX3* cell line using a lentiviral system ([Figure 3B](#F3){ref-type="fig"}) and tested its proliferative ability in response to RA by growth curve analyses. The results show that silencing *TBX3* reduces the impact of RA on the proliferation of the ME1402 cells, which was shown to be statistically significant when the data were subjected to a two-sample *t* test ([Figure 3B](#F3){ref-type="fig"}, left). Whereas the ME1402 cells show an almost 3.5-fold reduction in cell number by 9 d of RA treatment, the sh*TBX3* cells were less responsive under these conditions, showing a 2.5-fold reduction. Western blot analyses show that even in the knockdown *TBX3* cell line, RA treatment is still able to induce an increase in TBX3 protein levels, albeit to a much lesser extent than the parental cell line. These results suggest that, in *TBX3*-associated cancers, the reported antiproliferative effects of RA may be mediated partly through increasing *TBX3* expression.

![RA-mediated reduction in ME1402 cell numbers correlates with increased TBX3 levels. (A) Growth curve assay of ME1402 cells treated with vehicle or RA. Right, Western blot analysis of protein harvested from the growth curve assay. (B) Growth curve assay of ME1402 cells and *shTBX3*-ME1402 cells treated with vehicle or RA. Right, Western blot analysis of protein harvested from the growth curve assay. The bar graph compares the fold reduction in ME1402 and *shTBX3* cell numbers at day 9 of the growth curve assay. Bars, SD. \*p \< 0.05, \*\*p \< 0.001.](2362fig3){#F3}

Retinoic acid activates *Tbx3* expression during mouse embryonic development
----------------------------------------------------------------------------

As mentioned earlier, the RA signaling pathway plays an important role in the development of the heart, kidney, and limbs, and *Tbx3* has also been implicated in the development of these organs. We therefore speculated that the regulation of *TBX3* by RA in cancer might reflect a similar relationship during embryonic development. To explore this hypothesis, we used a limb organ culture assay to test whether RA could activate *Tbx3* in tissue. Limb buds were dissected from embryonic day 10.5 (E10.5) and E11.5 ICR mouse embryos and cultured in vitro for 72 h in serum-free medium with serum extender (which contains defined growth factors but no retinoids) with or without added RA. When analyzed for *Tbx3* expression by whole-mount in situ hybridization, the results show that in the presence of RA, *Tbx3* was appropriately expressed in the margins of the limb buds and in the flank ([Figure 4A](#F4){ref-type="fig"}). However, in the absence of RA, forelimb and hindlimb bud explants from both E10.5 and E11.5 embryos showed a modest but consistent decrease in *Tbx3* expression ([Figure 4A](#F4){ref-type="fig"}). Of interest, compared with E10.5 explants, *Tbx3* levels were lower in E11.5 forelimb and hindlimb cultures and appeared to be less RA responsive at this stage. It is worth noting that in the same culture system, when RA was depleted from E10.5 embryos by omitting fetal bovine serum (FBS) without serum extender a similar decrease in *Tbx3* expression was observed (unpublished data). As a positive control for this in vitro culture system, forelimb and hindlimb buds from E12.5 embryos were cultured in serum-free medium with or without RA and analyzed for expression of the RA-responsive gene RARβ, which is expressed in the handplate and footplate from E12.5 ([@B43]). The results in [Figure 4B](#F4){ref-type="fig"} indeed show a decrease in RARβ expression in the absence of RA. As an additional control, genital tracts from E11.5 embryos cultured as described for the limb buds showed decreased expression of the RA-responsive gene *Ret* ([@B13]) in the Wolffian duct ([Figure 4B](#F4){ref-type="fig"}). Taken together, these results suggest that RA is able to regulate *Tbx3* expression during mouse embryonic development.

![RA activates *Tbx3* expression during mouse embryonic development. (A) Whole-mount in situ hybridization with *Tbx3* probe of forelimb and hindlimb explants from E10.5 and E11.5 ICR mouse embryos cultured in serum-free medium with serum extender, with or without 200 nM all-*trans* and 9-*cis* RA for 72 h. (B) Left, whole-mount in situ hybridization with RARβ probe of handplates and footplates from E12.5 embryo forelimbs (FL) and hindlimbs (HL) cultured with or without RA. Right, whole-mount in situ hybridization with c-Ret probe of genital tracts from E11.5 embryos cultured with or without RA. Arrow indicates the Wolffian duct. (C) Left, whole-mount in situ hybridization of *Raldh2* wild-type and mutant E10.5 embryos using antisense *Tbx3* probe. Right, whole-mount in situ hybridisation of a wild-type E10.5 embryo with a sense *Tbx3* probe. Note that this embryo was damaged in dissection, and therefore two halves are shown. Genotypes are as indicated. (D) Whole-mount in situ hybridization showing *Tbx3* expression in handplates and footplates from E13.5 *Raldh2^+/−^* and *Raldh^−/−^* embryos. Right, handplates and footplates from a stage-matched E13.5 ICR embryo for comparison.](2362fig4){#F4}

We next investigated whether the regulation of *Tbx3* by RA could be demonstrated in vivo, using the retinaldehyde dehydrogenase 2--knockout (*Raldh2^−/−^*) mouse model, in which Raldh2, an enzyme required for most RA synthesis in the embryo, is inactivated. In these experiments a sense *Tbx3* probe was used as a negative control to confirm the specificity of the staining. At E10.5 the mutant embryos were much smaller than controls ([Figure 4C](#F4){ref-type="fig"}) and exhibited a pattern of malformations including craniofacial, heart, somite, and limb defects ([@B50]). Of interest, the intensity of *Tbx3* staining in the *Raldh2^−/−^* embryos was close to that seen for the *Raldh2^+/−^* and *Raldh2^+/+^* embryos ([Figure 4C](#F4){ref-type="fig"}). It is worth noting that in order to extend the life of the mutant embryos to E10.5, RA was administered in the food of the pregnant dam between E7.5 and E9.5 to circumvent lethal heart abnormalities. On the basis of previous studies, the half-life of RA under conditions used for dietary supplementation is 24 h or less ([@B46]), and hence by E10.5, it would not be surprising if residual RA was able to maintain *Tbx3* expression or delay its down-regulation in mutants. To address this possibility, we analyzed *Tbx3* expression in the mutants at later stages after cessation of supplementation at E9.5. At E13.5, forelimbs of the single mutant recovered were barely formed; however, hindlimbs were present and showed a decrease in *Tbx3* expression in the interdigital tissue compared with the control embryos ([Figure 4D](#F4){ref-type="fig"}). Because the mutant hindlimbs show a slight developmental delay compared with littermate controls, we compared *Tbx3* staining in the hind limbs of a stage-matched wild-type E13.5 ICR embryo, confirming that interdigital Tbx3 expression is diminished in the *Raldh2^−/−^* hindlimb compared with stage-matched controls. Although we were only able to recover a single *Raldh2* mutant, together with the in vitro results these data suggest that RA is able to regulate *Tbx3* expression during mouse embryonic development and that this may be a physiologically relevant relationship in limb morphogenesis.

DISCUSSION
==========

Alterations in TBX3 levels have catastrophic effects, as evidenced by haploinsufficiency of the human *TBX3* gene resulting in ulnar-mammary syndrome ([@B6]) and the overexpression of *TBX3* being associated with at least eight different types of cancers ([@B39]; [@B19]; [@B66]; [@B26]; [@B33]; [@B37]; [@B59]; [@B64]).The identification and understanding of biochemical pathways that regulate *TBX3* function are thus of critical importance. Here we demonstrate for the first time that the RA signaling pathway up-regulates *TBX3* mRNA and protein levels and we provide evidence that this up-regulation is a direct transcriptional effect mediated by binding of RA receptors to the *TBX3* promoter. Using both wild-type in vitro limb bud cultures and *Raldh2*-knockout mice lacking endogenous RA, we confirm that this regulation is relevant in mammalian systems.

Although RA signaling has long been known to play an essential role in embryogenesis and numerous RA-responsive genes have been identified, relatively few of these have been unequivocally shown to be direct targets of the RA--receptor complex ([@B4]). Among the well-known direct targets of RA signaling are the *RARβ* and *CYP26* genes, as well as *CRABP-II* and several members of the Hox gene family (*Hoxa1*, *Hoxa4*, *Hoxb1*, *Hoxb4*), all of which are activated by RA--receptor complexes binding to RAREs in their promoters ([@B67]; [@B2]; [@B20]; [@B54]; [@B22]; [@B55]; [@B34]). Our data reveal that the RA receptors bind a conserved RARE half-site at −75 base pairs in the *TBX3* promoter through which they activate *TBX3* expression and identify *TBX3* as a new direct target of RA signaling. It is worth noting that this half-site is common to two putative RAREs, involving half-sites at −87 and −59 base pairs. Although it is tempting to speculate that the RARE involving the evolutionarily highly conserved −87 half-site is more likely to be responsible for mediating RA-induced TBX3 expression, we cannot rule out the possibility that the site at −59 base pairs may also play a role. Furthermore, we show this positive regulation may be relevant during mouse embryonic development, since RA-depleted limb bud cultures of wild-type E10.5 and E11.5 mice have reduced *Tbx3* expression, and there is a loss of interdigital *Tbx3* expression in the hindlimbs of E13.5 *Raldh2* mutant embryos. The latter result in particular fits well with the role of RA signaling in the interdigital soft tissue recession required for digit separation. *RARβ;RARγ* double-mutant embryos show interdigital webbing up to E15.5 ([@B36]; [@B21]) and decreased interdigital apoptosis at E13.5 ([@B18]), which is also seen for E13.5 *Raldh2* mutants ([@B75]). Of interest, we demonstrate that *Tbx3* expression is lost in the interdigital mesenchyme of E13.5 *Raldh2* mutants, which is reminiscent of data reported by [@B75] for *RARβ*, *BMP-7*, and *MMP11* in *Raldh2* mutants. It is therefore possible that Tbx3, along with BMP-7 and MMP11, may mediate RA-induced apoptosis and tissue remodeling of the interdigital mesenchyme during digit separation. This suggestion is of particular interest in light of data from this study showing that the increase in TBX3 levels in RA-treated ME1402 cells correlated with decreased cell numbers.

It is worth noting that although *Tbx3* expression was lost in E13.5 Raldh2 mutant embryos, it was detected at E10.5. This may be explained by maternal RA administration from E7.5 to E9.5 to prevent lethal heart defects in Raldh2 mutants. Although supplemented RA is believed to be cleared by 24 h, as judged by an artificial promoter driving a LacZ reporter ([@B46]), it is also possible that its effects on RA-responsive endogenous gene expression may be sustained for a longer period. Indeed, defining the role of RA signaling in forelimb development, which is initiated at E9.5, has been difficult due to these technical problems and has led to some controversy ([@B71]; [@B62]; [@B44]; Niederreither *et al.*, 2002b; [@B74]; [@B76]; [@B14]; [@B65]). Nevertheless, we cannot discount the possibility that at this stage of embryogenesis, *Tbx3* is not responsive to RA. However, our data showing loss of interdigital *Tbx3* expression in an E13.5 Raldh2 mutant does suggest that *Tbx3* may be mediating RA signaling, at the very least, during handplate formation.

In addition to its role in embryogenesis, RA also holds potential as a chemotherapeutic agent through its ability to promote cell cycle arrest, differentiation, and apoptosis (reviewed in [@B70]). Elucidating downstream targets of RA signaling and their contributions to these antitumorigenic processes is therefore valuable for our understanding of how retinoid-based chemotherapies work. This has implications for identifying mechanisms to improve their efficacy, as well as sensitizing cancers known to be RA resistant. Taken together, our data showing that a robust increase in TBX3 expression corresponds with a decrease in the number of RA-treated melanoma cells and our observations that silencing *TBX3* in these cells reduces this effect suggest that *TBX3* may be one of the mediators of RA\'s chemotherapeutic activity. It is also in keeping with our previously published data implicating TBX3 as an antiproliferative factor in other cancer cell lines ([@B56]). This capacity of TBX3 to limit proliferation is in contrast to much of the literature, which describes TBX3 as a proproliferative factor that functions by repressing the cyclin-dependent kinase inhibitor p14^ARF^ (p19^ARF^ in mouse) to bypass senescence ([@B10]; [@B9]; [@B30]). Although these apparently opposing roles may seem contradictory, a similar duality is also seen in development. In the heart, *Tbx3* is expressed in the nonchamber myocardium of the atrioventricular canal, which has less proliferative ability than chamber myocardium ([@B25]; [@B23]). Ectopic expression of *Tbx3* results in suppression of chamber myocardium and a decrease in the number of dividing cells, whereas silencing *Tbx3* promotes proliferation ([@B60]; [@B3]). However, during liver development, formation of the liver is much smaller in *Tbx3*-null mice, and hepatoblasts isolated from these mice showed decreased proliferation and increased p19^ARF^ expression, suggesting that Tbx3 induces proliferation in hepatoblasts through repression of *p19^ARF^* ([@B68]). We suggest that the evidence supports dual roles for *TBX3* as a regulator of proliferation in both development and cancer, with its pro proliferative and antiproliferative functions dependent on cellular context, such as the regulation by RA signaling described in this study.

In conclusion, we present data that identify *Tbx3* as a novel direct target of RA signaling in mouse embryonic development and elucidate a mechanism by which this gene, the deregulated levels of which have dire consequences, is regulated. Furthermore, our observations that TBX3 is involved in mediating the antiproliferative effects of RA in melanoma cell lines suggest that it is potentially a novel target for anticancer drugs.

MATERIALS AND METHODS
=====================

Cell lines and culture conditions
---------------------------------

The human melanoma cell lines ME1402 and 501mel were maintained in RPMI 1640 medium (Highveld Biological, Lyndhurst, United Kingdom) supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin and maintained at 37°C in an atmosphere of 5% CO~2~. For RA treatment, we used 10 μM all-*trans* RA (Sigma-Aldrich, St. Louis, MO). For transcription inhibitor experiments, cells were pretreated with 5 μg/ml actinomycin D (Sigma-Aldrich) for 1 h and then treated with RA for 4 h. For inhibition of de novo protein synthesis experiments, cells were pretreated with 30 μg/ml cycloheximide (Sigma-Aldrich) for 1 h and then treated with RA for 4 h.

Western blot analysis
---------------------

Cells were harvested and solubilized at 4°C in radioimmunoprecipitation assay buffer (150 mM NaCl, 1% Triton X-100, 0.1% SDS, 20 mM Tris, pH 7.5, 1% deoxycholate, and a cocktail of protease inhibitors), centrifuged at 12,000 × *g* for 20 min at 4°C, and the supernatants recovered. Protein concentrations were determined using the bicinchoninic acid assay (Pierce, Rockford, IL), according to the manufacturer\'s instructions, with bovine serum albumin (BSA) as the standard. Equal amounts of protein were loaded and separated on 8--10% SDS-polyacrylamide gels and transferred to Hybond C (GE Healthcare Life Sciences, Amersham, United Kingdom). Membranes were blocked for 1 h at room temperature with phosphate-buffered saline (PBS) containing 5% nonfat dry milk, probed with appropriate primary antibodies, followed by peroxidase-conjugated anti-rabbit antibody (1:5000), and visualized by enhanced chemiluminescence (Pierce). The primary antibodies used were rabbit polyclonal anti-TBX3 (42-4800; Zymed, San Francisco, CA) and rabbit polyclonal anti-p38 (Sigma-Aldrich).

qRT-PCR
-------

Total RNA was extracted from cells using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA). Reverse transcription of RNA (1 μg) was performed according to the manufacturer\'s instructions using the InProm-II reverse transcription system (A3800; Promega, Madison, WI). Using 2 μl of cDNA, we conducted PCR with the SensiMix Lite Kit (QT 405-05; Quantace, Taunton, MA) according to the manufacturer\'s protocol. Real-time PCR was performed on a LightCycler Version 3 (Roche, Basle, Switzerland) using the following parameters: denaturation (15 min at 95°C), annealing and amplification at 35 cycles (15 s at 94ºC; 20 s at 55ºC; 20 s at 72°C), melting temperature (15 s at 65°C), and a cooling step (30 s at 40°C). Each DNA sample was quantified in duplicate, and a negative control without cDNA template was run with every assay to assess the overall specificity. Melting curve analyses were carried out to ensure product specificity, and data were analyzed using the 2^−ΔΔCt^ method. Relative mRNA expression levels were normalized to glucuronidase beta (GUSB) for each reaction with PCR efficiency correction calculated using the formula Ratio = E~target~CP~target~(control -- sample)/E~ref~CP~ref~(control -- sample), where E is the real-time PCR efficiency and CP is the crossing point. Primers used to amplify the human *TBX3* (QT00022484) and GUSB (QT00046046) were purchased from Qiagen.

Plasmid constructs
------------------

The human *TBX3* promoter luciferase reporter constructs have been described previously ([@B47]). The human pSG5-RARα and pSVL-RXRα expression plasmids were kindly provided by Pierre Chambon (Institut de Genetique et de Biologie Moleculaire et Cellulaire, Strasbourg, France). The pTIG-*shTBX3* lentiviral plasmid was a kind gift from Marco Weinberg (University of the Witwatersrand, Johannesburg, South Africa), who also designed and cloned the knockdown sequence into the pHIV7-TetRIRESeGFP vector (pTIG; [@B1]).

Transfection and luciferase assays
----------------------------------

Transient transfections were performed using FuGENE HD (Roche, Grenzach-Wyhlen, Germany) according to the manufacturer\'s instructions. We used 501 melanoma cells in these assays in place of ME1402 cells, as the latter have very low transfection efficiency. Cells were plated at 1.5 × 10^5^ cells/ml in 35-mm cell culture dishes 16 h before transfection. We cotransfected 501mel cells with 400 ng each of *TBX3*-luciferase vector and RARα and RXRα expression plasmids overnight. The next day, the medium was replaced with fresh medium containing RA and incubated at 37°C for a further 24 h. Cell extracts were assayed for firefly luciferase activity using the dual luciferase assay system (Promega, Madison, WI). Luciferase activities were measured using the Luminoskan Ascent Luminometer (Thermo Labsystems, Franklin, MA). All transfections were performed in duplicate, and at least three independent experiments were done to confirm reproducibility.

Site-directed mutagenesis of the TBX3 promoter
----------------------------------------------

The −141--base pair *TBX3*-luciferase plasmid was modified by site-directed mutagenesis using an adapted protocol based on the Stratagene QuikChange system using *Pfu* DNA polymerase (Promega). Mutations were introduced as follows. The right half-site of the RARE at --87 was mutated from CAATCA to GGATCC using the primer pair 5′-AAAGCGTCAAAGAGCGGATCCAGAG­GCCTCCGGCT-3′ and 5′-AGCCGGAGGCCTCTGGACCGCTC TTTGACGC­TTT-3′. Successful introduction of the mutation was confirmed by automated BigDye Terminator sequencing using the AB3100 Genetic Analyzer (Applied Biosystems, Foster City, CA).

DNA affinity immunoblot assay
-----------------------------

Biotinylated DNA probes spanning from −137 to +36 base pairs relative to the *TBX3* transcriptional start site were generated by PCR using primer pairs with the reverse primer containing a 5′-biotin modification (forward, 5′-CACTCGACCTGTGAAAACCAC-3′; reverse, 5′-Bio-AGAGCTCCTCGCCACCCT-3′). The −87 RARE wild-type and mutant *TBX3*-luciferase plasmids were used as templates. The probes were purified and immobilized on streptavidin coupled beads (Dynabeads M-280 streptavidin; Invitrogen, Carlsbad, CA) according to the manufacturer\'s instructions. Subconfluent ME1402 cells were treated with 10 μM RA for 4 h and nuclear extracts isolated as described previously ([@B20a]). For each DNA-binding reaction, 40 μg of nuclear extract was incubated with 1 μg of biotinylated DNA probe in 200 μl of binding buffer (20 mM Tris-HCl pH 7.6, 50 mM NaCl, 1 mM MgCl~2,~ 0.2 mM EDTA, 0.5 mM dithiothreitol, 5% glycerol, and 10 ng/μl poly(dI-dC)). The beads were extensively washed with binding buffer and boiled in 25 μl of 2× protein loading buffer (125 mM Tris-HCl, pH 6.5, 0.4% SDS, 10% β-mercaptoethanol, and 20% glycerol). Proteins bound to the biotinylated probes were analyzed by SDS--PAGE, followed by immunoblotting using rabbit polyclonal anti-RARα (C-20), anti-RARβ (C-19), anti-RARγ (C-19), and anti-RXRα (D-20) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).

Chromatin immunoprecipitation assays
------------------------------------

Chromatin immunoprecipitation assays were carried out as previously described ([@B57]). Briefly, ME1402 cells plated in 15-cm dishes at a total of (10--20) × 10^6^ cells were treated with RA for 4 h and then fixed in 1% formaldehyde at room temperature for 10 min. The reaction was quenched with 125 mM glycine, and cells were collected by scraping in PBS and lysed in lysis buffer (10 mM EDTA, 50 mM Tris-Cl, pH 8.1, 0.5% Nonidet P-40, 1% SDS) plus protease inhibitors. The chromatin was then sonicated to obtain fragments of 300--500 base pairs, precleared with protein A/G agarose beads (sc-2003; Santa Cruz Biotechnology), and incubated with 2 μg each of specific antibody (rabbit polyclonal anti-RARα \[C-20\], anti-RARβ \[C-19\], anti-RARγ \[C-19\], and anti-RXRα \[D-20\]) or 8 μg of nonspecific IgG (rabbit polyclonal IgG) (all Santa Cruz Biotechnology) at 4°C overnight. Five percent of supernatant volume was reserved as input. Samples were immunoprecipitated with protein A/G agarose beads, and washed and bound DNA was extracted and purified using a PCR purification kit (Qiagen) according to the manufacturer\'s instructions. PCR was conducted using GoTaq Green PCR Master Mix (Promega) with 4 μl of DNA in a final volume of 20 μl, using the following parameters: 5 min at 94°C for one cycle; 30 s at 94°C, 30 s at 54°C, 1 min at 60°C for 30 cycles; 7 min at 72°C for one cycle. PCR products were visualized after electrophoresis on a 2% agarose gel. The primer pairs used for PCR analysis were as follows: *TBX3* (forward, 5′-CTCAGCTCT­ATCCCCCAGCA-3′; reverse, 5′-CGCTCTTTCGCTCTCGAGGAG-3′) and GAPDH (forward, 5′-GAAGGCTGGGGCTCATTT-3′; reverse, 5′-CAGGAGGCATTGCTGATGAT-3′).

Lentiviral stable knockdown cell lines
--------------------------------------

ME1402 cells were transduced with vesicular stomatitis virus G--pseudotyped lentiviral particles essentially as described in [@B1]. Briefly, 5 × 10 cm dishes of HEK293T cells at ∼60% confluency were transfected using CaPO~4~ with 13 μg of the pTIG-shTBX3 lentiviral vector, 3.75 μg of the Gag--Pol packaging plasmid (pRRE), 3 μg of the Rev packaging plasmid (pRSV-Rev), and 3.75 μg of vesicular stomatitis virus G envelope plasmid (pVSVG) per dish. Forty-eight hours after transfection, virus supernatants were harvested and concentrated by ultracentrifugation at 25,000 rpm at 4°C for 2 h (SW 55 Ti; Optima L-80 XP; Beckman Coulter, Brea, CA) and the viral pellets resuspended in sterile PBS. ME1402 cells were transduced with concentrated viral particles in the presence of 8 μg/ml polybrene (hexadimethrine bromide; Sigma-Aldrich) overnight. A pure population of positively transduced cells was obtained by fluorescence-activated cell sorting for enhanced green fluorescent protein and successful knockdown of TBX3 in the *shTBX3*-ME1402 cells confirmed by Western blotting.

Growth curves
-------------

Short-term growth of the ME1402 and *shTBX3*-ME1402 cell lines was compared as described previously ([@B58]). Cells were seeded in triplicate at 10^4^ cells/well in 12-well plates, collected by trypsinization, and counted on a hemocytometer at 2- to 3-d intervals.

In situ hybridization and embryo culture
----------------------------------------

ICR female mice housed with male mice overnight were checked daily for vaginal plugs, with noon of the day a plug appeared taken as E0.5. Raldh2^−*/*+^ female mice (mated with Raldh2^−*/*+^ males) were supplied with all-*trans* retinoic acid in 1g of applesauce from E7.5 to E9.5 of gestation. On the first day the mouse received 150 μg RA, and on E8.5 and E9.5 the mouse received 400 μg. Pregnant females were killed on the appropriate day by cervical dislocation, embryos were collected in cold PBS containing BSA (Sigma-Aldrich), and extraembryonic tissues were removed. Mouse organ cultures were performed essentially as described previously, using a method shown to support limb bud outgrowth ([@B48]). Briefly, limb buds were dissected from E10.5 to E12.5 ICR embryos and cultured ventral side down on a 0.3 μM isopore membrane filter (Millipore, Billerica, MA) in Opti-MEM Reduced Serum Medium (Life Technologies, Carlsbad, CA) supplemented with 10% FBS or 5′ MITO+ Serum Extender (BD Biosciences, San Diego, CA) and 1% penicillin/streptomycin for 72 h at 37°C in 5% CO~2~. Genital ridges were dissected from E11.5 embryos and cultured dorsal side down as described for limb buds. For RA supplementation, 200 nM all-*trans* and 9-*cis* RA (Sigma-Aldrich) were added to the medium. Organ cultures were subsequently fixed and processed for in situ hybridization using standard protocols as previously described ([@B73]). Digoxigenin-labeled RNA probes were made using standard protocols. The mouse *Tbx3* template plasmid has been described previously ([@B11]), and the pBS-cRet and pBS-RARβ~Total~ plasmids were kindly provided by F. Costantini and C. Mendelsohn, respectively (Columbia University, New York, NY).

Statistical analysis
--------------------

Statistical analysis was performed by using the two-sample *t* test (Excel; Microsoft, Redmond, WA).
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RA

:   retinoic acid

Raldh

:   retinaldehyde dehydrogenase

RAR

:   retinoic acid receptor

RARE

:   retinoic acid response element

RXR

:   retinoid X receptor
